Recent developments in nuclear medicine in the management of bone metastases: A review and perspective

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 28, Issue 5, 2005, Pages 513-520

  Damerla, Venugopal ^a   Packianathan, S ^b   Boerner, Philip S ^b   Jani, Ashesh B ^c   Vijayakumar, Srinivasan ^b   Vijayakumar, Vani ^d  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Bone metastases; Breast; Cancer; Lung; Pain; Prostate; Radionuclides

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PARATHYROID HORMONE; PHOSPHORUS 32; RADIOPHARMACEUTICAL AGENT; RHENIUM 186; RHENIUM 188; SAMARIUM 153; STRONTIUM 89; TESTOSTERONE; TIN DERIVATIVE;

AWARENESS; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE METASTASIS; BONE PAIN; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC APPROACH ROUTE; EDUCATION PROGRAM; HUMAN; LEUKOPENIA; META ANALYSIS; METASTASIS INHIBITION; MORBIDITY; NUCLEAR MEDICINE; OUTCOMES RESEARCH; QUALITY OF LIFE; RADIOISOTOPE THERAPY; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT PLANNING;

BONE NEOPLASMS; DISEASE PROGRESSION; HUMANS; NUCLEAR MEDICINE;

EID: 26444544162     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000162425.55457.10     Document Type: Review

References (81)

1. Yau V, Chow E, Davis L, et al. Pain management in cancer patients with bone metastases remains a challenge. J Pain Symptom Manage. 2004;27:1-3.
2. Piffanelli A, Dafermou A, Giganti M, et al. Radionuclide therapy for painful bone metastases. An Italian multicentre observational study. Writing Committee of an Ad Hoc Study Group. Q J Nucl Med. 2001;45:100-107.
3. Dafermou A, Colamussi P, Giganti M, et al. A multicentre observational study of radionuclide therapy in patients with painful bone metastases: of prostate cancer. Eur J Nucl Med. 2001;28:788-798.
4. 89Sr in palliation in skeletal metastases. J Nucl Med. 1999;40:256-261.
5. 32P therapy revisited. Nucl Med Commun. 1999;20:697-702.
6. Rao DV, Radhamohan G. Pain palliation with testosterone potentiated orally administered sodium orthophosphate in patients with disseminated bone metastases: a preliminary study. Indian J Nucl Med. 2001;16:16-19.
7. 32P radiopharmaceuticals for the treatment of painful osseous metastases. Semin Nucl Med. 1992;22:17-27.
8. 153Sm-ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol. 2002;20:189-196.
9. 153Sm-EDTMP for painful bone metastases. Nucl Med Rev Cent East Eur. 2000;3:161-163.
10. 153Sm-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China. Eur J Nucl Med. 1999;26:2-7.
11. 153Sm lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol. 1998;16:1574-1581.
12. 153Sm-EDTMP in the palliative treatment of painful skeleton metastases: results of an IAEA international multicenter study [abstract]. J Nucl Med 2000;41(suppl):146P.
13. 188Re-HEDP in prostate cancer patients with osseous metastases. Eur J Nucl Med. 2000;27:123-130.
14. 188Re-HEDP therapy for the palliation of pain due to osseous metastases in lung cancer patients. Cancer Biother Radiopharm. 2003;18:719-726.
15. 186Re-1,1-hydroxyethylidene diphosphonate in the treatment of painful bone metastases. J Nucl Med. 2000;41:647-654.
16. 186Re-HEDP in multiple bone metastases. Nuklearmedizin. 1996;35:63-67.
17. 89Sr and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol. 1994;31:33-40.
18. 89Sr chloride therapy on bone pain palliation in patients with skeletal cancer metastases. Eur J Nucl Med. 1998;25:1362-1367.
19. 89Sr chloride: efficacy in relation to the degree of bone involvement. Eur J Nucl Med. 2000;27:1487-1493.
20. Turner SL, Gruenewald S, Spry N, et al. Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer. Br J Cancer. 2001;84:297-302.
21. Ashayeri E, Omogbehin A, Sridhar R, et al. 89Sr in the treatment of pain due to diffuse osseous metastases: a university hospital experience. J Natl Med Assoc. 2002;94:706-711.
22. 117mSn-(Stannic)-diethylene triamine pentaacetic acid: a phase I/II clinical study. Clin Cancer Res. 1998;4:61-68.
23. Solomayer EF, Diel IJ, Meyberg GC, et al. Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metas-tasis. Breast Cancer Res Treat. 2000;59:271-278.
24. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5-26.
25. Scarantino CW, Ornitz RD, Woodard SA. Metastases and disseminated disease. In: Clinical oncology: a multi-disciplinary approach for physicians & students. 8th ed. Philadelphia: WB Saunders; 2001:846-863.
26. Bonica JJ. Importance of effective pain control. Acta Anaesthesiol Scand Suppl. 1987;85:1-16.
27. Nielsen OS, Munro AJ, Tannock IF. Bone metastases: pathophysiology and management policy. J Clin Oncol. 1991;9:509-524.
28. Clark GM, Sledge GW Jr, Osborne CK, et al. Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol. 1987;5:55-61.
29. 32P for intractable bony pain from carcinoma of the prostate. Clin Oncol (R Coll Radiol). 1990;2:220-223.
30. Pecher C. Biological investigations with radioactive calcium and strontium: preliminary report on the use of radioactive strontium in the treatment of metastatic bone cancer. Univ Calif Publ Pharmacol. 1942;2:1117-1149.
31. Pandit-Taskar N, Batraki M, Divgi CR. Radiopharmaceutical therapy for palliation of bone pain from osseous metastases. J Nucl Med. 2004;45:1358-1365.
32. Silberstein EB. Systemic radiopharmaceutical therapy of painful osteoblastic metastases. Semin Radiat Oncol. 2000;10:240-249.
33. Silberstein EB. Painful osteoblastic metastases: the role of nuclear medicine. Oncol (Huntingt). 2001;15:157-163, 167-170, 174.
34. 153Sm-EDTMP therapy of disseminated skeletal metastasis. Eur J Nucl Med. 1989;15:784-795.
35. 89Sr therapy: strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med. 1986;12:447-454.
36. 89Sr radionuclide therapy: a dosimetric study using impulse response function analysis. Br J Radiol. 1987;60:685-692.
37. 89Sr radiotherapy of metastatic prostatic carcinoma. J Nucl Med. 1992;33:1316-1323.
38. 153Sm-EDTMP in metastatic cancer. J Nucl Med. 1989;30:1814-1818.
39. 186Re-(Sn)HEDP for treatment of multiple metastatic foci in bone: human biodistribution and dosimetric studies. Radiology. 1988;166:501-507.
40. 153Sm-labeled EDTMP for bone metastases from cancer of the prostate. Clin Oncol. 1992;4:160-164.
41. 89Sr therapy. J Nucl Med. 1994;35:1662-1664.
42. 32P-labeled phosphates. Semin Oncol. 1993;20(suppl 2):10-21.
43. Serafini AN. Therapy of metastatic bone pain. J Nucl Med. 2001;42:895-906.
44. 186Re-HEDP in breast cancer patients. Breast Cancer Res Treat. 2001;66:101-109.
45. 153Sm-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med. 1993;34:1839-1844.
46. Friedland J. Local and systemic radiation for palliation of metastatic disease. Urol Clin North Am. 1999;26:391-402.
47. Blitzer PH. Re-analysis of the RTOG study of the palliation of symptomatic osseous metastasis. Cancer. 1985;55:1468-1472.
48. Epstein LM, Stewart BH, Antunez AR, et al. Half and total body radiation for carcinoma of the prostate. J Urol. 1979;122:330-332.
49. Hoskin PJ. Radiotherapy in the management of bone pain. Clin Orthop. 1995;312:105-119.
50. Salazar OM, Rubin P, Hendrickson FR, et al. Single-dose half-body irradiation for palliation of multiple bone metastases from solid tumors. Final Radiation Therapy Oncology Group report. Cancer. 1986;58:29-36.
51. McQuay HJ, Collins SL, Carroll D, et al. Radiotherapy for the palliation of painful bone metastases. Cochrane Database Syst Rev. 2000;2:CD001793.
52. 89Sr and/or external radiotherapy. Urology. 1997;50:747-753.
53. Macklis R, Lasher J. Palliative radiotherapy for skeletal metastases: cost-substitution analyses and economic impact. J Oncol Manage. 1999;8:17-22.
54. Papatheofonis FJ. Short term reduction in pain medication costs following systemic radionuclide therapy in prostate cancer patients. Veterans Health Syst J. 1998;3:63-66.
55. Silberstein EB, Taylor Jr A. Procedure guideline for bone pain treatment 1.0. J Nucl Med. 1995;37:881-884.
56. 89Sr chloride for pain palliation in prostatic skeletal malignancy. Br J Radiol. 1991;64:816-822.
57. 153Sm-EDTMP as a bone imaging agent during a therapeutic trial [abstract]. J Nucl Med. 1991;32(suppl):918P.
58. Papatheofanis FJ. Variation in oncologic opinion regarding management of metastatic bone pain with systemic radionuclide therapy. J Nucl Med. 1999;40:1420-1423.
59. Schellhammer PF. Radical prostatectomy. Patterns of local failure and survival in 67 patients. Urology. 1988;31:191-197.
60. Wood Jr DP, Banks ER, Humphreys S, et al. Identification of bone marrow micrometastases in patients with prostate cancer. Cancer. 1994;74:2533-2540.
61. Hellman S, Weischselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8-10.
62. Singh D, Yi WS, Brasacchio RA, et al. Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int J Radiat Oncol Biol Phys. 2004;58:3-10.
63. Tang B, Vu M, Booker T, et al. TGF-β switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. J Clin Invest. 2003;112:1116-1124.
64. McCready VR, O'Sullivan JM. Future directions for unsealed source radionuclide therapy for bone métastases. Eur J Nucl Med Mol Imaging. 2002;29:1271-1275.
65. 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer. 1997;33:1583-1591.
66. Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet. 2001;357:336-341.
67. McEwan AJ. Use of radionuclides for the palliation of bone metastases. Semin Radiat Oncol. 2000;10:103-114.
68. 153Sm-ethylene diamine tetramethylene phosphonate. Eur J Cancer. 1991;27:1084-1086.
69. Schulte M, Brecht-Krauss D, Heymer B, et al. Grading of tumors and tumorlike lesions of bone: evaluation by FDG PET. J Nucl Med. 2000;41:1695-1701.
70. 186Re-HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone. Br J Cancer. 2002;86:1715-1720.
71. 131I-MIBG. J Nucl Med. 2001;42:1713-1721.
72. 186Re-HEDP treatment of skeletal metastases from prostate cancer. Eur J Nucl Med Mol Imaging. 2003;30:1114-1124.
73. 186Re-HEDP therapy depends on the number of metastases [abstract]. Radiology. 2001;221:344.
74. 89Sr therapy in patients with prostate cancer resistant to chemotherapy. Clin Nucl Med. 2004;29:81-85.
75. 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial. J Nucl Med. 2002;43:79-86.
76. Michaelson MD, Smith MR. Genitourinary malignancies. In: Giaccone G, Schilsky R, Sondel P, eds. Cancer chemotherapy and biological response modifiers. The Netherlands: Elsevier BV; 2003:547-564.
77. Body JJ, Bartl R, Burckhardt P, et al. Current use of bisphosphonates in oncology: International Bone and Cancer Study Group. J Clin Oncol. 1998;16:3890-3899.
78. Hamdy NA, Papapoulos SE. The palliative management of skeletal metastases in prostate cancer: use of bone-seeking radionuclides and bisphosphonates. Semin Nucl Med. 2001;31:62-68.
79. 89Sr (Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton. Eur J Nucl Med Mol Imaging. 2002;29:494-498.
80. Bouchet LG, Bolch WE, Goddu SM, et al. Considerations in the selection of radiopharmaceuticals for palliation of bone pain from metastatic osseous lesions. J Nucl Med. 2000;41:682-687.
81. 32P orthophosphate: implications for therapy of bone pain and bone metastases. J Nucl Med. 2000;41:941-951.